Abstract
BackgroundEpratuzumab is a humanized monoclonal antibody (mAb) that targets the B cell-specific protein CD22 and is currently in Phase 3 clinical trials in patients (pts) with systemic lupus erythematosus (SLE)....
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have